Clinical MilestoneThe completion of patient enrollment in the CENDIFOX study marks a significant clinical milestone, with study results expected to provide valuable data on treatment outcomes.
Financial PerformanceLisata announced 3Q24 financial results, posting EPS of ($0.59) compared to our estimate of ($0.77) and consensus of ($0.75).
Licensing AgreementA licensing agreement with Kuva Labs expands the potential use of certepetide beyond treatment into cancer diagnosis, creating significant added value.